Information Provided By: 
Fly News Breaks for July 24, 2017
ENDP, BDSI
Jul 24, 2017 | 08:16 EDT
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
News For BDSI;ENDP From the Last 2 Days
There are no results for your query BDSI;ENDP
